FutureChem Completes Phase 1 Clinical Trial of Prostate-Specific Antigen Targeted Diagnostic in the US

[Asia Economy Reporter Jang Hyowon] FutureChem, a radiopharmaceutical specialist company (CEO Ji Daeyoon), announced on the 3rd that the Phase 1 clinical trial of the prostate cancer diagnostic agent FC303 in the United States has been completed and the result report has been received.

This clinical trial was conducted at Johns Hopkins University in the United States, and the clinical result report evaluated that the safety and efficacy of FC303 are high regardless of race. It also accurately detected primary cancer as well as recurrent and metastatic lesions in bones, muscles, lungs, and major organs where cancer cells are prone to metastasize, and was evaluated to have diagnostic performance equal to or greater than the drug approved by the US FDA last year.

FutureChem's FC303 is a targeted diagnostic agent that targets the PSMA (Prostate Cancer Membrane Antigen) protein specifically expressed only in prostate cancer. FC303 is expected to be an effective imaging approach for identifying cancer metastasis to other areas compared to the most commonly used CT, MRI, and bone scans. It is also expected to greatly contribute to the optimized treatment of the prostate cancer therapeutic agent FC705 currently under development.

FC303 has also confirmed high safety and efficacy in domestic Phase 1 clinical trials. In particular, in terms of efficacy, the TBR (Tumor to Background Ratio) confirmed in PET imaging demonstrated performance suitable for nuclear medicine specialists to visually distinguish tumors, thereby verifying its efficacy.

A FutureChem official stated, “We plan to apply for Phase 2 clinical trials in the United States and are also considering technology export to the North American market, the largest market following Europe, China, and the MENA region.”

This content was produced with the assistance of AI translation services.